MannKind to Give Oral Presentation on Meal Challenge Results From the Afrezza® With Basal Combination (ABC Study) at 16th Annual ATTD Conference
- Inhaled Technosphere® Insulin (TI) lowered peak glucose levels 30 minutes faster than injectable rapid-acting insulin delivered through an AID insulin pump and significantly lowered post-prandial glucose (PPG) from 45-120 minutes after a controlled meal challenge test
MannKindis planning a larger switch study in type 1 diabetes (T1D) to evaluate inhaled insulin with once-daily basal insulin in patients that switch from rapid-acting insulin given through multiple daily injections or any insulin pump delivery system
The data showed that subjects utilizing inhaled Technosphere Insulin lowered peak glucose levels 30 minutes faster (200 mg/dl at 60 minutes) than subjects utilizing a rapid-acting analogue (RAA) with an Automated Insulin Delivery (AID) system (264 mg/dl at 90 minutes). Subjects utilizing TI also experienced a significantly lower mean PPG from 45 to 120 minutes post-meal.
“We believe inhaled insulin is an important option for those living with type 1 diabetes to reduce their PPG in the first 120 minutes,” said
“We are steadfast in our commitment to addressing the serious unmet need to improve mealtime control for those living with diabetes,” said
Twenty-six adults with type 1 diabetes using AID systems completed the pilot study. The inhaled TI group (21 participants) utilized an inhaled insulin dose to cover a standardized meal whereas the AID control group (five participants) used AID-administered RAA to cover the standardized meal. Each participant consumed 37g of a nutritional shake (1 can of Boost®). Glucose was measured by self-monitored blood glucose (SMBG) at 15–30-minute intervals over two hours. The inhaled TI dosing used in this trial simplified the conversion from RAA that is contained in the current prescribing information. This dosing regimen was reported in a recently published study showing this new dose conversion provides better PPG control and does not give rise to any new safety concerns such as severe hypoglycemia.
Additional analysis from the
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, Twitter or Instagram.
This press release contains forward-looking statements about the implications of clinical data and plans for future study that involve risks and uncertainties. Words such as “believes”, “anticipates”, “plans”, “expects”, “intends”, “will”, “goal”, “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that continued testing of an investigational drug product may not yield successful results or results that are consistent with earlier testing, as well as other risks detailed in MannKind’s filings with the
AFREZZA, TECHNOSPHERE and
MannKind: Christie Iacangelo, Corporate Communications (818) 292-3500 Email: firstname.lastname@example.org Rose Alinaya, Investor Relations (818) 661-5000 Email: email@example.com